KA
KRSA

Kovack Advisors’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Kovack Advisors’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,429
Closed -$15.5K – 1091
2026
Q1 		$15.5K Buy
+1,429
New +$2.03K ﹤0.01% 1008

Other funds holding KRSA

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Kovack Advisors's KRSA Position: Q2 2026 in Review

Kovack Advisors sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2026, closing a stake of 1,429 shares — an estimated $15.5K sold.

Kovack Advisors first reported a position in KRSA in Q1 2026 and held it in 1 quarter. The position peaked at $15.5K in Q1 2026. 21 funds tracked by Wall St. Rank hold KRSA as of Q2 2026.

  • Kovack Advisors reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Kovack Advisors sold 1,429 Korsana Biosciences, Inc. Common Stock shares in Q2 2026, an estimated $15.5K.
  • Kovack Advisors first reported a position in Korsana Biosciences, Inc. Common Stock in Q1 2026 and held it in 1 quarter.
  • Kovack Advisors's Korsana Biosciences, Inc. Common Stock position peaked at $15.5K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.